Enhancing T Cell Immunogenicity With Self-Amplifying RNA: Lessons from Arcturus’ Next-Gen Platform Development

• How to leverage self-amplifying RNA (saRNA) to increase antigen expression and prolong immune stimulation – and why this matters for robust T cell priming in cancer vaccines

• Comparative insights on saRNA vs. conventional mRNA for driving cellular immune responses, and where each platform may hold distinct clinical advantages

• Considerations for integrating saRNA into individualized vaccine workflows, including formulation, dosing strategy, and patient variability

Speakers: